Navigation Links
Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery
Date:11/2/2011

CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced that the analytical performance of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrated a 2-log improvement in sensitivity over today's ultrasensitive third-generation PSA assays used to measure PSA levels in patients following radical prostatectomy.  The results were published online by Clinical Chemistry.

"Quanterix has developed and validated a test that enables reliable measurements of PSA in men who have undergone radical prostatectomy for prostate cancer.  Following surgery, PSA levels typically drop to 'undetectable' with conventional third-generation tests, but we were able to accurately measure PSA with high precision in all samples evaluated," stated David Wilson Ph.D., Senior Director, Product Development at Quanterix and lead author of the study.  The analytical performance of this assay is further highlighted in the publication, and complements clinical data that has recently been published which suggests this test is a reliable predictor of five-year biochemical recurrence-free survival following surgery.  Dr. Wilson continued, "Increasing evidence suggests that a more sensitive PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically."

"Quanterix is developing a menu of high quality thoroughly characterized assays that will demonstrate the value of our SiMoA platform in both the life sciences and in vitro diagnostics markets.  These results provide another great example of how transformative sensitivity will allow us to deliver on the promise of next generation digital molecular diagnostics," said Martin Madaus, Ph.D., Chairman and CEO of Quanterix.  

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
2. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
3. Quanterix and STRATEC Announce Strategic Partnership
4. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
5. Quanterix Announces New Technology Evaluation Agreement
6. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
7. Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications
8. Clinical Integration Enables Leading Health Systems to Deliver Higher Quality, Cost-Effective Care
9. Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products
10. Molecular Devices Enables Intuitive Functionality at Your Fingertips on the Apple iPad with the Latest SoftMax Pro Software
11. Life Technologies Signs Exclusive License Agreement for TAL Effector Technology That Enables Synthetic Biologists to Precisely Control Gene Expression in Engineered Organisms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):